Dynamic 18F-Pretomanid PET imaging in animal models of TB meningitis and human studies

Filipa Mota1,2,3, Camilo A Ruiz-Bedoya1,2,3, Elizabeth W Tucker1,2,4

  • 1Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.

Nature Communications
|December 29, 2022
PubMed

Insights

Pretomanid effectively penetrates the central nervous system (CNS) for treating drug-resistant tuberculosis meningitis. However, the full BPaL regimen shows limited efficacy due to poor penetration of other drugs into the brain.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Neuroscience

Background:

  • Pretomanid, bedaquiline, and linezolid (BPaL) treat multidrug-resistant tuberculosis (MDR-TB).
  • Efficacy of BPaL for TB meningitis and CNS penetration are poorly understood.
  • MDR-TB meningitis has high mortality and limited treatment options.

Purpose of the Study:

  • To assess CNS penetration of pretomanid using novel 18F-pretomanid synthesis and PET imaging.
  • To evaluate the efficacy of the BPaL regimen in a TB meningitis mouse model.
  • To determine pretomanid CNS penetration in healthy human volunteers.

Main Methods:

  • Developed 18F-pretomanid for PET imaging.
  • Conducted cross-species PET imaging in mouse and rabbit TB meningitis models.
  • Assessed BPaL regimen efficacy in a mouse TB meningitis model.
  • Performed first-in-human 18F-pretomanid PET scans in healthy volunteers.

Main Results:

  • 18F-pretomanid demonstrated excellent CNS penetration in mouse and rabbit models.
  • Cerebrospinal fluid (CSF) pretomanid levels did not correlate with brain parenchyma concentrations.
  • BPaL regimen showed inferior bactericidal activity in the mouse model compared to standard TB treatment, likely due to poor bedaquiline and linezolid CNS penetration.
  • Human PET scans confirmed excellent pretomanid CNS penetration, with higher brain parenchyma than CSF levels.

Conclusions:

  • Pretomanid exhibits strong CNS penetration, suggesting potential for TB meningitis treatment.
  • Limited efficacy of the BPaL regimen in TB meningitis may stem from insufficient penetration of bedaquiline and linezolid into the brain.
  • Further research is needed to develop effective CNS-penetrant antibiotic regimens for MDR-TB meningitis.